Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term Follow-Up of Suprachoroidal RGX-314 in nAMD
NCT05210803Phase 2Enrolling by invitation
- Sponsor
- AbbVie Inc.
- Start
- Dec 2021
- Primary completion
- Jul 2031
- Modality
- Gene Editing, Gene Silencing, Gene Addition/Replacement
- Countries
- 1
01
Overview
A Phase 2 trial of surabgene lomparvovec in neovascular age-related macular degeneration (NVAMD), sponsored by AbbVie Inc.. Started Dec 2021; status: enrolling by invitation.
02
Drugs
surabgene lomparvovec
03
Conditions
neovascular age-related macular degeneration (NVAMD)
Beyond the preview
Go deeper on NCT05210803.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05210803.